Logo image of SPRB

SPRUCE BIOSCIENCES INC (SPRB) Stock Fundamental Analysis

NASDAQ:SPRB - Nasdaq - US85209E1091 - Common Stock - Currency: USD

0.0786  -0.05 (-39.45%)

After market: 0.0788 +0 (+0.25%)

Fundamental Rating

1

SPRB gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 553 industry peers in the Biotechnology industry. SPRB has a bad profitability rating. Also its financial health evaluation is rather negative. SPRB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SPRB had negative earnings in the past year.
In the past year SPRB has reported a negative cash flow from operations.
SPRB had negative earnings in each of the past 5 years.
In the past 5 years SPRB always reported negative operating cash flow.
SPRB Yearly Net Income VS EBIT VS OCF VS FCFSPRB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

SPRB's Return On Assets of -117.31% is on the low side compared to the rest of the industry. SPRB is outperformed by 79.43% of its industry peers.
SPRB has a worse Return On Equity (-184.02%) than 66.49% of its industry peers.
Industry RankSector Rank
ROA -117.31%
ROE -184.02%
ROIC N/A
ROA(3y)-72.45%
ROA(5y)-53.79%
ROE(3y)-104.69%
ROE(5y)-74.36%
ROIC(3y)N/A
ROIC(5y)N/A
SPRB Yearly ROA, ROE, ROICSPRB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SPRB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SPRB Yearly Profit, Operating, Gross MarginsSPRB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

More info and screens

3

2. Health

2.1 Basic Checks

SPRB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SPRB has been increased compared to 1 year ago.
SPRB has more shares outstanding than it did 5 years ago.
SPRB has a worse debt/assets ratio than last year.
SPRB Yearly Shares OutstandingSPRB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
SPRB Yearly Total Debt VS Total AssetsSPRB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

SPRB has an Altman-Z score of -10.85. This is a bad value and indicates that SPRB is not financially healthy and even has some risk of bankruptcy.
SPRB has a worse Altman-Z score (-10.85) than 76.77% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that SPRB is not too dependend on debt financing.
SPRB has a Debt to Equity ratio (0.00) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.85
ROIC/WACCN/A
WACC10.71%
SPRB Yearly LT Debt VS Equity VS FCFSPRB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 2.90 indicates that SPRB has no problem at all paying its short term obligations.
SPRB has a Current ratio of 2.90. This is in the lower half of the industry: SPRB underperforms 66.49% of its industry peers.
A Quick Ratio of 2.90 indicates that SPRB has no problem at all paying its short term obligations.
The Quick ratio of SPRB (2.90) is worse than 64.54% of its industry peers.
Industry RankSector Rank
Current Ratio 2.9
Quick Ratio 2.9
SPRB Yearly Current Assets VS Current LiabilitesSPRB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

SPRB shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.59%.
Looking at the last year, SPRB shows a very negative growth in Revenue. The Revenue has decreased by -51.31% in the last year.
EPS 1Y (TTM)-1.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-137.5%
Revenue 1Y (TTM)-51.31%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-75.86%

3.2 Future

Based on estimates for the next years, SPRB will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.56% on average per year.
Based on estimates for the next years, SPRB will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y54.58%
EPS Next 2Y20.38%
EPS Next 3Y4.69%
EPS Next 5Y13.56%
Revenue Next Year-68.59%
Revenue Next 2Y-81.91%
Revenue Next 3Y26.49%
Revenue Next 5Y-14.87%

3.3 Evolution

SPRB Yearly Revenue VS EstimatesSPRB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2030 2031 2032 50M 100M
SPRB Yearly EPS VS EstimatesSPRB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SPRB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SPRB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SPRB Price Earnings VS Forward Price EarningsSPRB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SPRB Per share dataSPRB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.38%
EPS Next 3Y4.69%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SPRB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SPRUCE BIOSCIENCES INC

NASDAQ:SPRB (4/28/2025, 8:00:02 PM)

After market: 0.0788 +0 (+0.25%)

0.0786

-0.05 (-39.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-15 2025-04-15/bmo
Earnings (Next)05-12 2025-05-12/amc
Inst Owners43.66%
Inst Owner Change0%
Ins Owners11.57%
Ins Owner Change0%
Market Cap3.32M
Analysts50
Price Target1.53 (1846.56%)
Short Float %0.11%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-76.4%
Min EPS beat(2)-166.11%
Max EPS beat(2)13.31%
EPS beat(4)3
Avg EPS beat(4)-28.73%
Min EPS beat(4)-166.11%
Max EPS beat(4)32.77%
EPS beat(8)6
Avg EPS beat(8)-5.91%
EPS beat(12)9
Avg EPS beat(12)-2.03%
EPS beat(16)12
Avg EPS beat(16)0.92%
Revenue beat(2)0
Avg Revenue beat(2)-41.64%
Min Revenue beat(2)-60.5%
Max Revenue beat(2)-22.79%
Revenue beat(4)2
Avg Revenue beat(4)-2.05%
Min Revenue beat(4)-60.5%
Max Revenue beat(4)69.52%
Revenue beat(8)6
Avg Revenue beat(8)79.98%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-18.18%
PT rev (3m)-18.18%
EPS NQ rev (1m)-17.11%
EPS NQ rev (3m)-17.11%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-20%
Revenue NQ rev (3m)-20%
Revenue NY rev (1m)-20%
Revenue NY rev (3m)-20%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.68
P/FCF N/A
P/OCF N/A
P/B 0.12
P/tB 0.12
EV/EBITDA N/A
EPS(TTM)-1.28
EYN/A
EPS(NY)-0.58
Fwd EYN/A
FCF(TTM)-1.33
FCFYN/A
OCF(TTM)-1.33
OCFYN/A
SpS0.12
BVpS0.68
TBVpS0.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -117.31%
ROE -184.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-72.45%
ROA(5y)-53.79%
ROE(3y)-104.69%
ROE(5y)-74.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.9
Quick Ratio 2.9
Altman-Z -10.85
F-Score2
WACC10.71%
ROIC/WACCN/A
Cap/Depr(3y)8.1%
Cap/Depr(5y)65.57%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-137.5%
EPS Next Y54.58%
EPS Next 2Y20.38%
EPS Next 3Y4.69%
EPS Next 5Y13.56%
Revenue 1Y (TTM)-51.31%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-75.86%
Revenue Next Year-68.59%
Revenue Next 2Y-81.91%
Revenue Next 3Y26.49%
Revenue Next 5Y-14.87%
EBIT growth 1Y-8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-114.46%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-68.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-68.19%
OCF growth 3YN/A
OCF growth 5YN/A